Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Prokarium logo — LIVING CURES

Prokarium

LIVING CURES

Founded 2012 United Kingdom London, United Kingdom 17 employees Unknown Total: $80.90M Biotechnology, Health Care +1

General Information

Company Name Prokarium
Founded Year 2012
Location United Kingdom London, United Kingdom +1
Employees 17
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Unknown
Social

Get notified when Prokarium moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Prokarium is demonstrating significant strategic activity, with its COO scheduled to discuss bacterial immunotherapies and clinical data at the prominent BIO event in June 2026. This industry engagement, coupled with a substantial 87.9% overhaul of their company website in the same month, indicates a concerted effort to enhance visibility and communicate recent advancements. These actions collectively suggest the company is preparing for a new phase of growth, potentially involving significant announcements or a new funding round.

Signal Types
Event Participation Website Update Marketing
Strategic Labels
Industry Engagement Communication Refresh Clinical Advancement
Next Move: Fundraising
·
Impact: 8/10
·
Ideal For: Biotech VCs — Growth Stage, Oncology Investors

About Prokarium

Prokarium, founded in 2012 and headquartered in the United Kingdom, is carving a niche in the innovative field of microbial immunotherapy. With the slogan "LIVING CURES," the company is developing cutting-edge treatments that harness recent advances in cancer immunology to revolutionize immuno-oncology.

Their lead program particularly targets bladder cancer, aiming to set a new benchmark in treatment paradigms through orchestrated, immune-driven, and enduring antitumor effects. By focusing on these advancements, Prokarium positions itself at the forefront of the biotechnology and pharmaceutical industries.

Most recently, the company secured a $6.28M Convertible Note investment on 01 December 2025 from NVEST VENTURE. This injection of capital underscores strong investor confidence in the company's potential to deliver transformative healthcare solutions and further expand its innovative pipeline.

Taxonomy: Microbial Immunotherapy, Immuno-Oncology, Bladder Cancer Treatment, Cancer Immunology, Biopharmaceutical, Synthetic Biology, Vaccine Development, Oral Delivery Systems, Immune-Driven Antitumor Effects, Oncology Therapeutics, Cancer Treatment Paradigm, Long-Lasting Immunotherapy, Re-engineered Evolution, Cancer Immunotherapy, Biotechnology Platform

Services & Products

Development of novel immunotherapies
Research and development of bacterial-based treatments for cancer
Discovery and clinical trial activities

Target Customers

Pharmaceutical companies Biotechnology firms Oncology researchers Cancer treatment centers

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note •••••• 1
Investor
01 Dec 2025
Grant •••••• 1
Investor
01 Aug 2024
Late Vc •••••• - 01 Feb 2023
Series B •••••• 4
Investor Investor Investor Investor
01 Oct 2020
Early VC •••••• 1
Investor
01 Oct 2019

View All 10 Funding Rounds

Prokarium Alternatives & Competitors

View All Alternatives
Prokarium vs
Alv B AS
Alv B AS Norway

COMPARATIVE ONCOLOGY & IMMUNOTHERAPY

12 employees
Biotechnology
Prokarium vs
Caedo Oncology AS
Caedo Oncology AS Norway

We create improved treatment options for cancer patients through unique immunotherapy opportunities

Series Unknown
6 employees
Biotechnology, Health Care
Prokarium vs
APAC Biotech
APAC Biotech

A Biotechnology Company focused on Research and Manufacturing Of Cell Based Immunotherapy treatment...

14 employees
Biotechnology, Health Care
View all alternatives

FAQ About Prokarium

LIVING CURES
Prokarium was founded in 2012.
Prokarium is headquartered in London, United Kingdom.
Prokarium operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Prokarium has approximately 17 employees.
Prokarium has completed 10 funding rounds, raising a total of $80.90M. The latest funding stage is Unknown.
Prokarium offers: Development of novel immunotherapies, Research and development of bacterial-based treatments for cancer, Discovery and clinical trial activities.
Top alternatives and competitors to Prokarium include Alv B AS, Caedo Oncology AS, APAC Biotech, Pangea Biomed, UNC Lineberger Comprehensive Cancer Center. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Prokarium and Alv B AS are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Prokarium and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy